Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Retension Pharmaceuticals, Inc.RTSN · Entity 184313 | Director | October 13, 2026 | October 13, 2026 |
| WATERS CORP /DE/WAT · Entity 3080 | Director | August 13, 2021 | August 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Retension Pharmaceuticals, Inc.
Report date October 13, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,666 |
Ending reported balance
After 2026-10-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-13 · Conversion · Acquired 4,026 · Balance 4,026 F1: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. Row 2 · 2026-10-13 · Conversion · Acquired 2,640 · Balance 6,666 F2: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-10-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-13 · Conversion · Disposed 4,026 · Balance 0 F1: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-10-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-13 · Conversion · Disposed 2,640 · Balance 0 F2: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date.
F2: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date.
WATERS CORP /DE/
Report date August 13, 2021 · Filed August 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,449 |
Reported balance
After 2021-08-13 transaction · row 1
1 source rowRow 1 · 2021-08-13 · Sale · Disposed 806 · Balance 16,449 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2026 Filed Oct 13, 2026 22:10 UTC | Retension Pharmaceuticals, Inc. RTSN · Entity 184313 | ConversionSeries B Convertible Preferred Stock · Derivative | 2,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-109154 · ownership.xml · derivative · entry 4 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,640 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. F2 · price: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. Read SEC document |
| October 13, 2026 Filed Oct 13, 2026 22:10 UTC | Retension Pharmaceuticals, Inc. RTSN · Entity 184313 | ConversionSeries A Convertible Preferred Stock · Derivative | 4,026 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-109154 · ownership.xml · derivative · entry 3 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,026 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. Read SEC document |
| October 13, 2026 Filed Oct 13, 2026 22:10 UTC | Retension Pharmaceuticals, Inc. RTSN · Entity 184313 | ConversionCommon Stock | 2,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-109154 · ownership.xml · nonDerivative · entry 2 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. Read SEC document |
| October 13, 2026 Filed Oct 13, 2026 22:10 UTC | Retension Pharmaceuticals, Inc. RTSN · Entity 184313 | ConversionCommon Stock | 4,026 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-109154 · ownership.xml · nonDerivative · entry 1 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. Read SEC document |
| October 08, 2026 Filed Oct 9, 2026 01:39 UTC | Retension Pharmaceuticals, Inc. RTSN · Entity 184313 | GrantStock Option (right to buy) · Derivative | 5,636 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001213900-26-108190 · ownership.xml · derivative · entry 1 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,636 Underlying: Common Stock · 5,636 shares Expires 2036-10-08 F1 · security: Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. F1 · derivative.exercise_date: Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| August 13, 2021 Filed Aug 16, 2021 14:32 UTC | WATERS CORP /DE/ WAT · Entity 3080 | SaleCommon Stock | 806 | $403.12 | $324,914.72 |
DisclosureSEC source: 0001127602-21-023712 · form4.xml · nonDerivative · entry 1 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,449 Read SEC document |
| August 12, 2021 Filed Aug 13, 2021 14:41 UTC | WATERS CORP /DE/ WAT · Entity 3080 | SaleCommon Stock | 4,000 | $398.43 | $1,593,720.00 |
DisclosureSEC source: 0001127602-21-023634 · form4.xml · nonDerivative · entry 1 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,255 Read SEC document |
| May 24, 2021 Filed May 25, 2021 14:15 UTC | WATERS CORP /DE/ WAT · Entity 3080 | SaleCommon Stock | 1,161 | $318.24 | $369,476.64 |
DisclosureSEC source: 0001127602-21-017964 · form4.xml · nonDerivative · entry 1 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,255 Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 18:51 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 1,352 | $0.00 Strike: $250.15 | $0.00 |
DisclosureSEC source: 0001127602-21-000949 · form4.xml · derivative · entry 2 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,352 Underlying: Common Stock · 1,352 shares Expires 2031-01-04 F2 · shares: Options fully vest on January 4, 2022. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 18:51 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 439 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-000949 · form4.xml · nonDerivative · entry 1 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,416 F1 · shares: Grant of shares of common stock subject to restrictions that lapse January 4, 2022 Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 16:48 UTC | WATERS CORP /DE/ WAT · Entity 3080 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $78.10 | $0.00 |
DisclosureSEC source: 0001127602-20-028562 · form4.xml · derivative · entry 3 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.underlying_shares: These stock options, granted on January 3, 2011, vested 20% per annum for a five year period and expire on January 3, 2021. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 16:48 UTC | WATERS CORP /DE/ WAT · Entity 3080 | SaleCommon Stock | 4,000 | $230.10 | $920,400.00 |
DisclosureSEC source: 0001127602-20-028562 · form4.xml · nonDerivative · entry 2 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,977 Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 16:48 UTC | WATERS CORP /DE/ WAT · Entity 3080 | Exercise / conversionCommon Stock | 4,000 | $78.10 | $312,400.00 |
DisclosureSEC source: 0001127602-20-028562 · form4.xml · nonDerivative · entry 1 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 19:58 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 1,601 | $0.00 Strike: $235.06 | $0.00 |
DisclosureSEC source: 0001127602-20-000495 · form4.xml · derivative · entry 5 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,601 Underlying: Common Stock · 1,601 shares Expires 2030-01-02 F4 · derivative.exercise_date: Options fully vest on January 2, 2021. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 19:58 UTC | WATERS CORP /DE/ WAT · Entity 3080 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $61.63 | $0.00 |
DisclosureSEC source: 0001127602-20-000495 · form4.xml · derivative · entry 4 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2020-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Acquisition of common stock was made under a sale plan established pursuant to the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 19:58 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 467 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-000495 · form4.xml · nonDerivative · entry 3 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,977 F3 · shares: Grant of shares of common stock subject to restrictions that lapse January 2, 2021. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 19:58 UTC | WATERS CORP /DE/ WAT · Entity 3080 | SaleCommon Stock | 4,000 | $234.93 | $939,720.00 |
DisclosureSEC source: 0001127602-20-000495 · form4.xml · nonDerivative · entry 2 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,510 F2 · date: Sale of common stock was made under a sale plan established pursuant to the requirements of Rule 10b5-1 under the Securities and Exchange Act of 1934, as amended. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 19:58 UTC | WATERS CORP /DE/ WAT · Entity 3080 | Exercise / conversionCommon Stock | 4,000 | $61.63 | $246,520.00 |
DisclosureSEC source: 0001127602-20-000495 · form4.xml · nonDerivative · entry 1 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Acquisition of common stock was made under a sale plan established pursuant to the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 15:33 UTC | WATERS CORP /DE/ WAT · Entity 3080 | SaleCommon Stock | 3,000 | $239.64 | $718,920.00 |
DisclosureSEC source: 0001127602-19-008264 · form4.xml · nonDerivative · entry 1 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,510 Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 18:48 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 1,760 | $0.00 Strike: $183.41 | $0.00 |
DisclosureSEC source: 0001127602-19-001139 · form4.xml · derivative · entry 5 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,760 Underlying: Common Stock · 1,760 shares Expires 2029-01-02 F4 · derivative.exercise_date: Options fully vest on January 2, 2020. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 18:48 UTC | WATERS CORP /DE/ WAT · Entity 3080 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $38.09 | $0.00 |
DisclosureSEC source: 0001127602-19-001139 · form4.xml · derivative · entry 4 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Acquisition of common stock was made under a sale plan established pursuant to the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 18:48 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 599 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-001139 · form4.xml · nonDerivative · entry 3 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,510 F3 · shares: Grant of shares of common stock subject to restrictions that lapse January 2, 2020. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 18:48 UTC | WATERS CORP /DE/ WAT · Entity 3080 | SaleCommon Stock | 3,500 | $184.74 | $646,590.00 |
DisclosureSEC source: 0001127602-19-001139 · form4.xml · nonDerivative · entry 2 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,911 F2 · date: Sale of common stock was made under a sale plan established pursuant to the requirements of Rule 10b5-1 under the Securities and Exchange Act of 1934, as amended. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 18:48 UTC | WATERS CORP /DE/ WAT · Entity 3080 | Exercise / conversionCommon Stock | 3,500 | $38.09 | $133,315.00 |
DisclosureSEC source: 0001127602-19-001139 · form4.xml · nonDerivative · entry 1 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Acquisition of common stock was made under a sale plan established pursuant to the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:09 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 2,692 | $0.00 Strike: $195.69 | $0.00 |
DisclosureSEC source: 0001127602-18-000574 · form4.xml · derivative · entry 5 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,692 Underlying: Common Stock · 2,692 shares Expires 2028-01-02 F4 · derivative.exercise_date: Options fully vest on January 2, 2019. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:09 UTC | WATERS CORP /DE/ WAT · Entity 3080 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $76.75 | $0.00 |
DisclosureSEC source: 0001127602-18-000574 · form4.xml · derivative · entry 4 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Acquisition of common stock was made under a sale plan established pursuant to the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:09 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 562 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-000574 · form4.xml · nonDerivative · entry 3 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,911 F3 · shares: Grant of shares of common stock subject to restrictions that lapse January 2, 2019. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:09 UTC | WATERS CORP /DE/ WAT · Entity 3080 | SaleCommon Stock | 3,500 | $194.58 | $681,030.00 |
DisclosureSEC source: 0001127602-18-000574 · form4.xml · nonDerivative · entry 2 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,349 F2 · date: Sale of common stock was made under a sale plan established pursuant to the requirements of Rule 10b5-1 under the Securities and Exchange Act of 1934, as amended. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:09 UTC | WATERS CORP /DE/ WAT · Entity 3080 | Exercise / conversionCommon Stock | 3,500 | $76.75 | $268,625.00 |
DisclosureSEC source: 0001127602-18-000574 · form4.xml · nonDerivative · entry 1 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Acquisition of common stock was made under a sale plan established pursuant to the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 10, 2017 Filed May 11, 2017 15:08 UTC | WATERS CORP /DE/ WAT · Entity 3080 | SaleCommon Stock | 1,000 | $174.01 | $174,010.00 |
DisclosureSEC source: 0001127602-17-017644 · form4.xml · nonDerivative · entry 1 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,349 Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 20:42 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 3,626 | $0.00 Strike: $136.43 | $0.00 |
DisclosureSEC source: 0001127602-17-001024 · form4.xml · derivative · entry 2 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,626 Underlying: Common Stock · 3,626 shares Expires 2027-01-03 F2 · derivative.exercise_date: Options fully vest on January 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 20:42 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 806 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-001024 · form4.xml · nonDerivative · entry 1 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,349 F1 · shares: Grant of shares of common stock subject to restrictions that lapse January 3, 2018. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 14:45 UTC | WATERS CORP /DE/ WAT · Entity 3080 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $48.88 | $0.00 |
DisclosureSEC source: 0001127602-16-069220 · form4.xml · derivative · entry 2 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2017-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 14:45 UTC | WATERS CORP /DE/ WAT · Entity 3080 | Exercise / conversionCommon Stock | 4,000 | $48.88 | $195,520.00 |
DisclosureSEC source: 0001127602-16-069220 · form4.xml · nonDerivative · entry 1 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2016 Filed Jan 5, 2017 20:11 UTC Amendment | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 3,761 | $0.00 Strike: $130.35 | $0.00 |
DisclosureSEC source: 0001127602-17-001010 · form4a.xml · derivative · entry 2 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,761 Underlying: Common Stock · 3,761 shares Expires 2026-01-04 F1 · shares: The purpose of this amended filing is to correctly report the number of stock and stock option awards. F3 · derivative.exercise_date: Options fully vest on January 4, 2017. Read SEC document |
| January 04, 2016 Filed Jan 5, 2017 20:11 UTC Amendment | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 843 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-001010 · form4a.xml · nonDerivative · entry 1 BERENDT MICHAEL J · CIK 0001186877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,543 F1 · shares: The purpose of this amended filing is to correctly report the number of stock and stock option awards. F2 · shares: Grant of shares of common stock subject to restrictions that lapse January 4, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.